Lesson From A Deal Gone Bad: Basilea Ups Role In New Astellas Partnership
Executive Summary
Even before Switzerland's Basilea started arbitration proceedings a year ago against its now former partner Johnson & Johnson on antibiotic ceftobiprole, the biotech would have been drawing lessons on what to avoid - and what to insist upon -in future license agreements
You may also be interested in...
Almirall Will Sell Basilea's Eczema Drug In 10 European Markets, Plus Mexico
The company's distribution agreement with Almirall does not change Basilea's 2010 sales guidance for its eczema drug Toctino, execs said.
Almirall Will Sell Basilea's Eczema Drug In 10 European Markets, Plus Mexico
The company's distribution agreement with Almirall does not change Basilea's 2010 sales guidance for its eczema drug Toctino, execs said.
Basilea Recovers With Astellas Deal For Phase III Anti-Fungal Following J&J Break-Up
Deal brings CHF75 million upfront plus welcome validation after Basilea's break-up with J&J on ceftobiprole.